Masahiro Kagabu
Overview
Explore the profile of Masahiro Kagabu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jo A, Shoji T, Otsuka H, Abe M, Tatsuki S, Chiba Y, et al.
Int J Clin Oncol
. 2025 Jan;
30(2):229-240.
PMID: 39812928
Doxorubicin + cisplatin and paclitaxel + carboplatin are standard chemotherapy regimens for endometrial cancer. The development of PD-1 and PDL-1 antibody drugs has led to the use of these agents...
2.
Ito R, Kagabu M, Sato S, Takatori E, Kaido Y, Nagasawa T, et al.
Int J Clin Oncol
. 2025 Jan;
30(3):559-569.
PMID: 39755760
Background: The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites,...
3.
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594756
: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions. : A total of 81...
4.
5.
Sato S, Shoji T, Jo A, Otsuka H, Abe M, Tatsuki S, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061184
Ovarian cancer (OC), accounting for approximately 200,000 deaths worldwide annually, is a heterogeneous disease showing major differences in terms of its incidence, tumor behavior, and outcomes across histological subtypes. In...
6.
Takahashi N, Seki T, Sasaki K, Machida R, Ishikawa M, Yunokawa M, et al.
Jpn J Clin Oncol
. 2024 Jul;
54(10):1078-1083.
PMID: 39023439
Background: The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing...
7.
Chiba Y, Kagabu M, Osakabe M, Ito R, Sato S, Takatori E, et al.
Jpn J Clin Oncol
. 2024 Jan;
54(4):424-433.
PMID: 38251744
Background: The Proactive Molecular Risk Classifier for Endometrial Cancer has identified four risk groups for the prognosis of endometrial cancer. Lenvatinib plus pembrolizumab was recently approved as a second-line treatment...
8.
Maekawa S, Takata R, Sekiguchi K, Kagabu M, Toyoshima M, Tamada S, et al.
Jpn J Clin Oncol
. 2023 Dec;
54(4):489-497.
PMID: 38157885
Objective: The companion diagnosis for olaparib, a poly (ADP-ribose) polymerase inhibitor for prostate cancer, aims to detect BRCA1/2 gene variants. In clinical practice, the frequency of germline BRCA1/2 variants in...
9.
Nagasawa T, Shoji T, Takatori E, Kaido Y, Kagabu M, Shimizu D, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958375
Recurrent non-squamous cell carcinoma (non-SCC) of the uterine cervix is resistant to treatment and has a poor prognosis. The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent...
10.
Akashi H, Yachida N, Ueda H, Yamaguchi M, Yamawaki K, Tamura R, et al.
Mol Cancer Ther
. 2023 Sep;
23(1):106-116.
PMID: 37717249
BRCA1/2 mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, BRCA1/2 mutations in clear cell ovarian carcinoma (CCC) are less frequent compared with high-grade serous ovarian cancer...